Y521 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ä®½·Ã¤³ÎÂ÷´ÜÁ¦ | Calcium-channel blockers causing adverse effects in therapeutic use |
 |
Y522 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Ç׺ÎÁ¤¸ÆÁ¦ | Other antidysrhythmic drugs, NEC causing adverse effects in therapeutic use |
 |
Y523 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº °ü»óµ¿¸ÆÈ®ÀåÁ¦ | Coronary vasodilators, NEC causing adverse effects in therapeutic use |
 |
Y523 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â µðÇǸ®´Ù¸ô | Dipyridamole causing adverse effects in therapeutic use |
 |
Y524 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò¾ïÁ¦Á¦ | Angiotensin-converting-enzyme inhibitors causing adverse effects in therapeutic use |
 |
Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Ç×°íÇ÷¾ÐÁ¦ | Other antihypertensive drugs, NEC causing adverse effects in therapeutic use |
 |
Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Å©·Î´Ïµò | Clonidine causing adverse effects in therapeutic use |
 |
Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸¾Æ³×Ƽµò | Guanethidine causing adverse effects in therapeutic use |
 |
Y525 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¶ó¿ì¿ùÇÇ¾Æ | Rauwolfia causing adverse effects in therapeutic use |
 |
Y526 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°íÁöÁúÇ÷Áõ ¹× Ç×µ¿¸Æ°æÈÁõ ¾à¹° | Antihyperlipidemic and antiarteriosclerotic drugs causing adverse effects in therapeutic use |
 |
Y527 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸»ÃÊÇ÷°üÈ®ÀåÁ¦ | Peripheral vasodilators causing adverse effects in therapeutic use |
 |
Y527 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´ÏÄÚÆ¾»êÀ¯µµÃ¼ | Nicotinic acid derivatives causing adverse effects in therapeutic use |
 |
Y528 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Á¤¸Æ·ùÁ¦, °æÈÁ¦ Æ÷ÇÔ | Antivaricose drugs, including sclerosing agents causing adverse effects in therapeutic use |
 |
Y529 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½ÉÇ÷°ü°èÅë¿¡ ÀÏÂ÷ÀûÀ¸·Î ¿µÇâÀ» ÁÖ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ ¾à¹° | Other and unspecified agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use |
 |
Y53 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting the gastrointestinal system causing adverse effects in therapeutic use |
 |
Y530 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È÷½ºÅ¸¹Î H2-¼ö¿ëü±æÇ×Á¦ | Histamine H2-receptor antagonists causing adverse effects in therapeutic use |
 |
Y531 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×»êÁ¦ ¹× Ç×À§»êºÐºñÁ¦ | Other antacids and anti-gastric-secretion agents causing adverse effects in therapeutic use |
 |
Y532 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÈïºÐ¼º ¼³»çÁ¦ | Stimulant laxative causing adverse effects in therapeutic use |
 |
Y533 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½Ä¿°¼ö¿Í »ïÅõÄ¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼º ¼³»çÁ¦ | Saline and osmotic laxatives causing adverse effects in therapeutic use |
 |
Y534 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¼³»çÁ¦ | Other laxatives causing adverse effects in therapeutic use |
 |